Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals is a privately held oncology drug development and discovery company.
| Company | Cylene Pharmaceuticals, Inc. |
|---|---|
| URL | http://www.cylenepharma.com/ |
Cylene Pharmaceuticals Initiates Phase I Trial with CX-4945
Breakthrough First-in Class Inhibitor of CK2
Cylene Pharmaceuticals Promotes Claire S. Padgett to Vice President of Clinical Operations
Cylene Pharmaceuticals has promoted Claire S. Padgett to Vice President of Clinical Operations. Ms. Padgett brings more than twenty-five years of experience in establishing and managing operations for organizations in the biotechnology,
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research
Cylene Pharmaceuticals is pleased to announce the addition of Dr. David M. Ryckman to its management team, where he will serve as Vice President of Manufacturing and Pharmaceutical Operations. With nearly 20 ye...
Cylene Pharmaceuticals' Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
SAN DIEGO, June 28 /PRNewswire/ -- Cylene Pharmaceuticals has initiated a single-agent Phase II clinical trial of its lead Ribosomal RNA Biogenesis Inhibitor, quarfloxin (CX-3543), in patients wi...
Targeted small molecule oncology compound, CX-3543, acts by inhibiting ribosomal RNA biogenesis
Financing Co-Led by HBM BioVentures and Lilly Ventures
Cylene Pharmaceuticals Initiates Phase I Clinical Trial for CX-3543, a First-in-Class Agent for Multiple Cancers
Cylene Pharmaceuticals, an oncology drug discovery and development company, today announced that it has initiated a Phase I clinical trial for CX-3543, its lead candidate for the treatment of multiple cancers. CX-3543 i...
Cylene Pharmaceuticals Initiates Phase I Clinical Trial for CX-3543, a First-in-Class Agent for Multiple Cancers
Cylene Pharmaceuticals, an oncology drug discovery and development company, today announced that it has initiated a Phase I clinical trial for CX-3543, its lead candidate for the treatment of multiple cancers. ...
Cylene Pharmaceuticals, an oncology drug discovery and development company, today announced the completion of a $26.3 million Series B financing, led by Coastview Capital. The funding will allow Cylene to advance CX-3543...
Cylene Pharmaceuticals Moves Headquarters and R&D Operations to State-of-the-Art San Diego Facility
Cylene Pharmaceuticals, an oncology drug discovery and development company, today announced that it has relocated its corporate headquarters and R&D operations to 5820 Nancy Ridge Drive Suite 200, in the heart of Sa...
11/01/2010MVC Corporation Changes Name to Mitsui & Co. Global Investment, Ltd.
11/01/2010MCVP Changes Name and Relocates Office
09/27/2010Notice on Relocation of MVC Head Office
09/24/2010Mitsui Ventures invested USD 5 M in S*BIO
06/17/2008 | Taro InabaBoehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.